Evidence map›Paper›PMID 33174061›Full record

ArticleMolecular medicine reports2020

TERF1 downregulation promotes the migration and invasion of the PC3 prostate cancer cell line as a target of miR‑155.

Wei Chen, Li-Na He, Yong Liang, Xiang Zeng, Cui-Ping Wu, Ming-Qiang Su, Yang Cheng, Jian-Hui Liu

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Prognostic value of TERF1 expression in prostate cancer.Journal of the Egyptian National Cancer Institute · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wei ChenDepartment of Science and Education, Zigong Fourth People's Hospital, Zigong, Sichuan 643000, P.R. China.
Li-Na HeDepartment of Reproductive Medicine, Zigong Maternity and Child Healthcare Hospital, Zigong, Sichuan 643000, P.R. China.
Yong LiangDepartment of Urology, Zigong Fourth People's Hospital, Zigong, Sichuan 643000, P.R. China.
Xiang ZengDepartment of Urology, Zigong Fourth People's Hospital, Zigong, Sichuan 643000, P.R. China.
Cui-Ping WuDepartment of Science and Education, Zigong Fourth People's Hospital, Zigong, Sichuan 643000, P.R. China.
Ming-Qiang SuDepartment of Urology, Zigong Fourth People's Hospital, Zigong, Sichuan 643000, P.R. China.
Yang ChengDepartment of Urology, Zigong Fourth People's Hospital, Zigong, Sichuan 643000, P.R. China.
Jian-Hui LiuDepartment of Urology, Zigong Fourth People's Hospital, Zigong, Sichuan 643000, P.R. China.
Zigong First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Telomeric repeat binding factor 1 (TERF1) has been identified as a tumor suppressor gene in numerous types of human cancer. However, the expression of TERF1 and its mechanism in prostate cancer (PCa) remains unclear. The present study aimed to explore the expression and functions of TERF1 in PCa. The UALCAN database was used to analyze the differential expression of TERF1 between normal prostate tissue and primary PCa tissue. Cell apoptosis was analyzed by Annexin V/propidium iodide staining, and wound healing and Transwell assays were used to detect the cell migration and invasion abilities, respectively. The cell viability was analyzed using an MTT assay. Reverse transcription‑quantitative PCR and western blotting were used to analyze the mRNA and protein expression levels, respectively, of epithelial‑mesenchymal transition (EMT) markers following TERF1 knockdown in the PC3 cell line. A dual luciferase reporter assay was used to verify the association between TERF1 and microRNA (miR)‑155 predicted by bioinformatics analysis. Rescue experiments were performed to determine the role of the miR‑155/TERF1 axis in regulating the cellular behaviors of PCa. The results demonstrated that the expression levels of TERF1 in the primary prostate tumors were significantly downregulated compared with in prostate normal tissue. TERF1 silencing was discovered to significantly promote cell viability, migration and invasion, while suppressing cell apoptosis. The impact of TERF1 on PC3 cells was suggested to occur through the EMT pathway. TERF1 was confirmed to be the direct target of miR‑155. The overexpression of miR‑155 promoted the viability, migration and invasion, while suppressing the apoptosis of the PC3 cell line, while the knockdown of miR‑155 in PC3 cells achieved the opposite trends. In addition, TERF1 overexpression reversed the promotive effects of upregulated miR‑155 expression levels on the migration and apoptosis of PC3 cells. On the contrary, the knockdown of TERF1 reversed the migration and apoptosis abilities of the downregulated miR‑155 expression levels on the cellular behaviors of PC3 cells. In conclusion, TERF1, as a direct target of miR‑155, was discovered to be significantly downregulated in PCa, which was suggested to promote the migration and invasion of PCa via the EMT pathway.

Indexed as

ApoptosisCell Line, TumorCell MovementCell ProliferationCell SurvivalEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMaleMicroRNAsNeoplasm InvasivenessPC-3 CellsProstateProstatic NeoplasmsRNA, Long NoncodingRNA, MessengerMicroRNAsMIRN155 microRNA, humanRNA, Long NoncodingRNA, MessengerShelterin ComplexTelomere-Binding ProteinsTERF1 protein, human

Identifiers

PMID33174061
PMCPMC7646979
OpenAlexW3094459165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.